AMAG Pharmaceuticals — Corporate Update (September 2018)
21 slides from AMAG Pharmaceuticals's corporate update, Sep 26, 2018
Slide 1: AMAG-423 Digoxin Immune Fab (ovine) (DIF) for the Treatment of Severe Preeclampsia
AMAG-423 Digoxin Immune Fab (ovine) (DIF) for the Treatment of Severe Preeclampsia September 26, 2018 © 2018 AMAG Pharmaceuticals, Inc. All rights reserved 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, the
Slide 3: Speakers / Agenda
Speakers / Agenda • Transaction terms • Severe preeclampsia condition • Commercial opportunity Bill Heiden President and Chief Executive Officer • DEEP study and secondary analysis results • The role of EDLFs in preeclampsia • Phase 2b/3a trial status • Development and regulatory timeline Julie Krop
Slide 4: Growing Innovative Pipeline
Growing Innovative Pipeline Approved/ PHASE 1 PHASE 2 PHASE 3 Regulatory Review Marketed AMAG-423 Digoxin Immune Treatment of severe preeclampsia Fab (ovine) (DIF) Treatment of low desire or libido with PDUFA TM AdCom: early Q1-2019 Vyleesi associated distress in postmenopausal 03/23/19 women Treatm
Slide 5: AMAG-423 DIF for the Treatment of Severe Preeclampsia
AMAG-423 DIF for the Treatment of Severe Preeclampsia • Financial terms to acquire global rights to DIF for the treatment of severe preeclampsia • Severe preeclampsia: Disease overview • Significant unmet medical need and global commercial opportunity • Endogenous digitalis-like factors (EDLF) in pr
Slide 6: Transaction Leverages AMAG's Development & Commercial Capabilities and Resources
Transaction Leverages AMAG’s Development & Commercial Capabilities and Resources Accelerate Development Timeline for a Potential Treatment with a Significant Unmet Medical Need July 2015 September 2018 • Entered into exclusive option to acquire DIF • Acquired rights to develop and market DIF for for
Slide 7: Preeclampsia and Severe Preeclampsia: No Effective Treatment
Preeclampsia and Severe Preeclampsia No Effective Treatment • Preeclampsia is a multi-system disorder that occurs only during pregnancy and the postpartum period and affects both the mother and unborn baby1 – Increasing at a rate faster than obesity and diabetes2 • Condition is characterized by hype
Slide 8: Preeclampsia: Unmet Medical Need is Substantial
Preeclampsia: Unmet Medical Need is Substantial Significant Burden to Healthcare System • Often results in premature births1, leading to serious health consequences for the baby2 – Intraventricular hemorrhage: bleeding in the brain – Necrotizing enterocolitis: severe inflammation of the bowels – Lif
Slide 9: Significant Market Opportunity
Significant Market Opportunity AMAG-423 • FDA granted orphan status (7-years exclusivity expected upon approval) and fast track review Estimated U.S. market • No current treatments for preeclampsia opportunity4 – Only “treatment” is delivery of the baby, often times very preterm1 • Ex-U.S. estimated
Slide 10: EDLFs: Contribution to Hypertension and Preeclampsia
EDLFs: Contribution to Hypertension and Preeclampsia Rationale to Study DIF • EDLFs are circulating inhibitors of the Na+ K+ ATPase pump (“sodium pump”)1 – Inhibit the sodium potassium ATPase pump, which can lead to vasoconstriction, elevated blood pressure, and decreased blood flow • EDLFs have bee
Slide 11: DEEP Trial: Small Proof of Concept Study
DEEP Trial1: Small Proof of Concept Study Positive Trends across Multiple Endpoints Double-blind, placebo-controlled, randomized trial to evaluate the effect of DIF administration on maternal and fetal outcomes in severe preeclampsia Study population and eligibility criteria Results • DIF (Digibind®
Slide 12: DEEP Trial: Sodium Pump Activity (Surrogate for EDLF Activity)
DEEP Trial1: Sodium Pump Activity (Surrogate for EDLF Activity) DIF Significantly Decreased EDLF Activity (Increased Sodium Pump Function) Sodium Pump Activity 30 25 20 n=19 15 n=15 n=21 n=22 10 5 n=20 n=12 n=21 0 n=19 -5 % Change from baseline from Change % -10 p=0.05 p=0.10 p=0.07 0-12h 12-24h 24-
Slide 13: Change in Creatinine Clearance and Relationship with EDLF Levels
Change in Creatinine Clearance and Relationship with EDLF Levels Statistically Significant Preservation of Creatinine Clearance Decline in Placebo Renal Function in DIF Treated Women1 Group Correlated to EDLF Levels2 (measured by sodium pump activity) (mL/min) 10 0 0 n=15 -10 (mL/min) -10 -20 -30 -2
Slide 14: Secondary Endpoints: Selected Maternal Outcomes in EDLF Positive Patients
Secondary Endpoints: Selected Maternal Outcomes in Patients Who Were EDLF Positive at Baseline1 Trends in Improvements in Maternal Outcomes in DIF Treated Patients Compared to Placebo Blurred Vision Use of Antihypertensives Pulmonary Edema p=0.136 p=0.117 p=0.035 70% 70% 70% n=12 60% 60% 60% 50% 50%
Slide 15: Selected Neonatal Outcomes in Infants Delivered by EDLF Positive Mothers
Selected Neonatal Outcomes in Infants Delivered by EDLF Positive Mothers at Baseline 1 78% of women were EDLF Positive1 Nonreassuring Fetal Status* Intraventricular Hemorrhage 50% p=0.136 50% p=0.015 n=8 40% 40% 30% 30% n=4 n=5 20% 20% 10% 10% % of neonates with IVH with neonates of % nonreassuring
Slide 16: Evaluation of Neonatal Outcomes to be Used in Current Phase 2b/3a Study
Evaluation of Neonatal Outcomes to be Used in Current Phase 2b/3a Study DEEP Trial: Selected Neonatal Outcome Measures1 Intraventricular Hemorrhage (IVH) Necrotizing Enterocolitis (NEC) Deaths Severe (grades 3 and 4) 15% 15% 15% p=0.24 p=0.61 p=0.49 n=3 n=3 10% 10% 10% n=2 5% Deaths neonatal 5% n=1
Slide 17: Significant Clinical and Mechanistic Evidence Supports Further Development
Significant Clinical and Mechanistic Evidence Supports Further Development Study Conclusions • EDLFs elevated in 78%1 of patients in DEEP trial (similar to a previous trial2) • Increased EDLF levels correlated with decline in creatinine clearance • Subjects who were EDLF positive showed better respo
Slide 18: Phase 2b/3a Study Design
Phase 2b/3a Study Design • Study design: – Multi-center, randomized, double-blind, placebo-controlled, parallel group study with DigiFab® – Dosing every 6 hours for 4 days • Study population: – 200 antepartum subjects with severe preeclampsia between 23 weeks/0 days and 31 weeks/6 days • Endpoints:
Slide 19: Development and Regulatory Timeline
Development and Regulatory Timeline Q3-2018 Q4-2018 Q1-2019 Q2-2019 Q3-2019 Q4-2019 Q1-2020 Q2-2020 Q3-2020 Q4-2020 AMAG acquires global Accelerate patient enrollment in Topline data NDA filing rights to develop and Phase 2b/3a trial market DIF for treatment of severe preeclampsia MATERNAL HEALTH: A
Slide 20: Summary AMAG-423
SUMMARY AMAG-423 • Addresses a serious unmet medical need with significant global commercial potential • Mechanism of action of DIF has strong scientific rationale • Proof of concept study demonstrated consistent and encouraging trends in improving neonatal and maternal outcomes with no significant
Slide 21: AMAG-423 Digoxin Immune Fab (ovine) (DIF) for the Treatment of Severe Preeclampsia
AMAG-423 Digoxin Immune Fab (ovine) (DIF) for the Treatment of Severe Preeclampsia September 26, 2018 © 2018 AMAG Pharmaceuticals, Inc. All rights reserved 21
AMAG Pharmaceuticals — Corporate Update (September 2018) on 6ix